Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Pfizer
Incyte Corporation
EMD Serono
Boehringer Ingelheim
Exelixis
Varian, a Siemens Healthineers Company
Hoffmann-La Roche
Seagen Inc.
Novartis
NantCell, Inc.
Bristol-Myers Squibb
Delfi Diagnostics Inc.
Pfizer
AstraZeneca
Intuitive Surgical
Amgen
BeiGene
Shanghai Escugen Biotechnology Co., Ltd
Sanofi
Alpha Biopharma (Jiangsu) Co., Ltd.
Intuitive Surgical
Hutom Corp
Incyte Corporation
Incyte Corporation
Incyte Corporation
Daiichi Sankyo
Navigation Sciences, Inc.
Takeda
Novita Pharmaceuticals, Inc.
Quantum Surgical
Trishula Therapeutics, Inc.
Nuvation Bio Inc.
Hoffmann-La Roche
Sidekick Health
NanOlogy, LLC
Median Technologies
Johnson & Johnson (China) Investment Ltd.
Johnson & Johnson Enterprise Innovation Inc.
Revolution Medicines, Inc.
Alethia Biotherapeutics
EpicentRx, Inc.
Akeso
Labcorp Corporation of America Holdings, Inc
Auris Health, Inc.
Intensity Therapeutics, Inc.
Gene Solutions
Novartis
Compugen Ltd
Novartis